Treatment Resistant Depression Drug Pipeline Analysis Report 2024

According to John Hopkins Medicine, treatment resistant depression affects around 30% of the people with major depressive disorder. Young adults and late teens are at a higher risk of developing the condition. As a result, finding effective treatment alternatives is a key area of interest amongst the leading institutes and healthcare companies.

Key Takeaways

• Major companies involved in the treatment resistant depression pipeline drugs market include Eli Lilly and Company, Axsome Therapeutics, Inc., and Janssen Research & Development, LLC

• Leading drugs currently under pipeline include Tianeptine, NV-5138, and Minocycline among others.

• Regulatory authorities such as the United States FDA and EMA play an essential role in the drug pipeline for treatment resistant depression as they are offering breakthrough designations to manage the condition.

Report Coverage 

The treatment resistant depression Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into treatment resistant depression drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Treatment resistant depression. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The treatment resistant depression pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from treatment resistant depression. 

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to treatment resistant depression.

Treatment Resistant Depression Drug Pipeline Outlook 

Treatment resistant depression  is a major depressive disorder, characterized by the ineffectiveness of at least two different antidepressants to improve the state of an individual. Common symptoms include longer and persistent depressive episodes, anxiety, suicidal ideation and behaviour and Anhedonia (reduced ability to experience pleasure).

SSRIs (selective serotonin reuptake inhibitors) or SNRIs (serotonin and norepinephrine reuptake inhibitors) are the first-line antidepressants used to treat the condition. Moreover, therapies like electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) can also be advised based on the symptoms and severity of the patient. To manage the condition more effectively, the FDA approved Exxua, a new drug to treat major depressive disorder in adults. An antidepressant that selectively targets the serotonin 1A receptor, this drug does not have any common side effects associated with other medications. Such approvals indicate a robust pipeline for several treatment resistant depression drugs in the coming years.

Treatment Resistant Depression – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of treatment resistant depressiondrugs based on several segmentations including: 

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase.

• Late-Stage Products (Phase 3 and Phase 4)

• Mid-Stage Products (Phase 2)

• Early-Stage Products (Phase I)

• Preclinical and Discovery Stage Products

By Drug Class

EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes: 

• Atypical Antipsychotics

• Tricyclic Antidepressants (TCAs)

• Monoamine Oxidase Inhibitors (MAOIs)

• Serotonin Modulators

• Mood Stabilizers and Anticonvulsants

By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.

• Oral

• Parenteral

• Others

Treatment Resistant Depression – Pipeline Assessment Segmentation, By Phases 

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for treatment resistant depression. There are around 134 drugs in phase II of treatment resistant depression drugs.

Treatment Resistant Depression – Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under treatment resistant depressionpipeline analysis include atypical antipsychotics, tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), serotonin modulators, mood stabilizers and anticonvulsants. Tricyclic antidepressants such as Amitriptyline, Nortriptyline, and Imipramine are conventional medications. However, they have a higher side effect profile. Ketamine is advised for patients who have not responded to other treatments.

Treatment Resistant DepressionClinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR report for the treatment-resistant depressiondrug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in treatment resistant depression clinical trials:

• Eli Lilly and Company

• Janssen Research & Development, LLC

• Axsome Therapeutics, Inc.

• Relmada Therapeutics, Inc.

• GH Research Ireland Limited

• Jiangsu Hansoh Pharmaceutical Co., Ltd.

• Navitor Pharmaceuticals, Inc.

Treatment Resistant Depression– Emerging Drugs Profile 

Tianeptine

New York State Psychiatric Institute is evaluating Tianeptine to treat resistant depression. The study is expected to be conducted in two parallel wings, which include the Mood and Anxiety Disorders Program at the Icahn School of Medicine and the Stanford Depression Research Clinic at Stanford University School of Medicine (SUSM). The study will enroll around 75 patients who have failed to respond to at least 2 adequate treatment trials.

NV-5138

Sponsored by Navitor Pharmaceuticals Inc., this drug is in Phase 1 of a randomized, two-part, placebo-controlled study. It is under evaluation for its efficacy, tolerability and efficacy against treatment resistant depression.

Minocycline

Currently in Phase 3 of a 12 week, double-blind, placebo-controlled trial, Minocycline is under evaluation as an add-on treatment for treating patients who have not responded to antidepressant treatment. The study is sponsored by the Centre for Addiction and Mental Health.

Reasons To Buy This Report 

The Treatment Resistant Depression Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for treatment resistant depression. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within treatment resistant depression pipeline insights.

Key Questions Answered in the Treatment Resistant Depression– Pipeline Insight Report

• What is the current landscape of treatment resistant depression pipeline drugs?

• How many companies are developing treatment resistant depression drugs? 

• How many phase III and phase IV drugs are currently present in treatment resistant depression pipeline drugs? 

• Which companies/institutions are leading the treatment resistant depression drug development? 

• What is the efficacy and safety profile of treatment resistant depression pipeline drugs? 

• What are the opportunities and challenges present in the treatment resistant depression drug pipeline landscape? 

• Which company is conducting major trials for treatment resistant depression drugs? 

• What geographies are covered for treatment resistant depression clinical trials? 

• What are emerging trends in treatment resistant depression clinical trials?

Related Reports

Treatment Resistant Depression Market

Global Anxiety and Depression Treatment Market 

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market